Tolerability and observation package
Frame the package around the first decision your team needs from the data.
Preclinical proof for thymosin beta-4 fragment research peptide
Build TB-500 evidence before managing a lab.
VivoProof acts as a preclinical proof layer for drug builders. Start with a TB-500 research question, then turn it into a scoped evidence plan for systems, samples, endpoints, data closeout, and feasibility review.
TB-500 requests often need a practical first study that separates tolerability, material handling, and endpoint feasibility before a more specific repair model is planned.
Decision first
Start with the decision the data must support.
A useful request is not just a compound name. It names the decision, the system, the readouts, the reporting standard, and the constraints that could change feasibility.
Repair or tissue endpoint feasibility
Map the system, comparator, sample schedule, and endpoint burden before review.
Necropsy, tissue collection, and histology add-on
Decide whether the first pass needs exposure, tolerability, biomarkers, or tissue work.
Lot-to-lot or comparator planning
Specify the closeout standard so the raw tables and summary are useful after the run.
Evidence systems
Choose the smallest credible system for the question.
Many teams start by asking for animal testing. The right first package can also be a cell screen, dish assay, bioanalysis run, or tissue package when that is the smaller credible step.
Organism-level signal
Use when route, tolerability, exposure, metabolic, behavioral, or tissue-level questions cannot be answered in a dish.
Early signal before animals
Use when viability, pathway, direct-cell, or assay feasibility can reduce risk before an in vivo package.
Exposure and sample data
Use for LC-MS/MS, plasma exposure, sample handling, biomarker panels, or material-dependent readouts when available.
Local endpoint package
Use when tissue collection, necropsy, histology, imaging, or local-reaction review is part of the decision.
Inputs before scope
What a real TB-500 request needs.
The Proof Planner can draft a useful starting point, but the formal review depends on material documents, assay availability, sample burden, and the closeout package your team needs.
Material and study inputs
- Identity documents, storage needs, and available material
- Endpoint domain, comparator structure, and preferred model if known
- Required final files, image needs, and timeline constraints
Endpoint options
- Clinical observations, body weight, and chemistry panels
- Tissue collection, histology, or image-based readouts when feasible
- Deviation notes and source-document references
What can change feasibility
Model specificity and tissue workflow create the largest spread between a simple screen and a meaningful endpoint study.
Output package
What your team gets back.
VivoProof coordinates the proof package and closeout so the output is useful for internal review, sponsor diligence, or the next experimental decision.
- Study assumption sheet
- Subject-level observation and endpoint exports
- Study summary with sample inventory and custody notes
- Start with the TB-500 question and available material context.
- Select the system, confidence level, sample map, and closeout format in Proof Planner.
- Complete contact and payment-method verification before exact estimate release.
- Feasibility, review path, and next action are confirmed online — no call required.
Public pages avoid protocols, dosing directions, treatment claims, and human-use instructions. Detailed plans are finalized only after research-use review, compound-document review, and facility review.
Next step
Design the TB-500 evidence plan online.
Build a first-pass proof package for the research question, system, samples, closeout, and planning range. The formal scope is locked only after qualified review.